| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, ISO 9001 |
| Suitable for: | Elderly, Adult |
| State: | Powder |
| Purity: | >98% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Product name | Rapamycin Powder |
| Other Name: | Sirolimus |
| Appearance: | White Powder |
| CAS NO. | 53123-88-9 |
| M.F.: | C51H79NO13 |
| M.W.: | 914.19 |
| Specification: | 99% |
Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and to treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing the production of interleukin-2 (IL-2)
Anti-fungal, anti-inflammatory, anti-tumor and immunosuppressive properties.
Rapamycin is a triene macrolide antibiotic, which demonstrates anti-fungal, anti-inflammatory, anti-tumor and immunosuppressive properties. Rapamycin has been shown to block T-cell activation and proliferation, as well as, the activation of p70 S6 kinase and exhibits strong binding to FK-506 binding proteins.
Rapamycin also inhibits the activity of the protein, mTOR, (mammalian target of rapamycin) which functions in a signaling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signaling pathway.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}